Abstract: Plant-protecting mixtures of active ingredients having a synergistically increased action, wherein component I is a compound having a plant-immunizing action of the formula I ##STR1## in which Z is CN, COOH or a salt thereof, CO--OC.sub.1 -C.sub.4 alkyl or CO--SC.sub.1 -C.sub.4 alkyl;and wherein component II is a compound selected from the group consisting of propiconazole, difenoconazole, penconazole, fenpropimorph, fenpropidine, cyprodinil, metalaxyl, R-metalaxyl and pyroquilon.
Type:
Grant
Filed:
March 31, 1999
Date of Patent:
September 12, 2000
Assignee:
Novartis Finance Corp.
Inventors:
Wilhelm Ruess, Gertrude Knauf-Beiter, Ruth Beatrice Kung, Helmut Kessmann
Abstract: A method is disclosed for iontophoretically removing any compound that is capable of causing skin irritation or other harmful effects. More specifically, a bipolar iontophoretic transdermal delivery method is disclosed that includes a reversal phase for controlling the iontophoretic transdermal delivery of pharmaceutical compounds while reducing or eliminating skin irritation and terminating the pharmacological or toxicological effects in skin of drugs/cosmetics/active ingredients which form a drug depot in the skin after passive or iontophoretic application.
Type:
Grant
Filed:
January 29, 1997
Date of Patent:
January 25, 2000
Assignee:
Novartis Finance Corp.
Inventors:
Steven Minh Dinh, Parminder Bobby Singh, Ann Reese Comfort
Abstract: In a tubular pressure chamber a drop of a DNA solution with gold particles suspended therein is atomized at the opening of a cannula by a pressure impact. The fog droplets containing the gold particles and the DNA entrained by them, are pressured by the pressure impact through a restriction at the end of the pressure chamber and thereby accelerated and focused. They subsequently traverse in free flight an evacuated specimen chamber and impact in a narrowly limited target area with a predetermined pulse, cells fixed on a holder, thereby penetrating them.
Abstract: The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0,R is one or more substituents selected from halogen, alkyl, trifluoromethyl and alkoxy; andR.sub.1 and R.sub.2 are each independently of the other alkyl, or phenyl that is unsubstituted or substituted by halogen, trifluoromethyl, alkyl or by alkoxy, it also being possible for one of the two radicals R.sub.1 and R.sub.2 to be hydrogen, or R1 and R2 together form an alkylene chain having from 2 to 5 carbon atoms that is unsubstituted or substituted by alkyl; or salts thereof. Compounds of formula I inhibit protein kinases, for example the tyrosine protein kinase of the receptor for the epidermal growth factor, EGF.